FORTREA HOLDINGS INC. (FTRE) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $227.80M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -2.59× | Operating cash flow / net income. Period ending 2026-06-30. $227.80M ÷ $-88.00M ≈ -2.59× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 227.80M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | 2.68B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -88.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $227.80M | (m) | (m) | $2.68B | (m) | $-88.00M | (m) | (m) | (m) | -2.59× |
| 2026-03-31 | (m) | (m) | $220.70M | (m) | (m) | $2.71B | (m) | $-449.70M | (m) | (m) | (m) | -0.49× |
| 2025-12-31 | (m) | (m) | $113.50M | (m) | (m) | $2.72B | (m) | $-986.20M | (m) | (m) | (m) | -0.12× |
| 2025-09-30 | (m) | (m) | $1.50M | (m) | (m) | $2.76B | (m) | $-1.01B | (m) | (m) | (m) | -0.00× |
| 2025-06-30 | (m) | (m) | $-87.70M | (m) | (m) | $2.73B | (m) | $-1.03B | (m) | (m) | (m) | 0.09× |
| 2025-03-31 | (m) | (m) | $164.20M | (m) | (m) | $2.69B | (m) | $-790.40M | (m) | (m) | (m) | -0.21× |
| 2024-12-31 | (m) | (m) | $262.80M | (m) | (m) | $2.70B | (m) | $-328.50M | (m) | (m) | (m) | -0.80× |
| 2024-09-30 | (m) | (m) | $264.10M | (m) | (m) | $2.71B | (m) | $-321.80M | (m) | (m) | (m) | -0.82× |
| 2024-06-30 | (m) | (m) | $268.40M | (m) | (m) | $2.75B | (m) | $-307.90M | (m) | (m) | (m) | -0.87× |
| 2024-03-31 | (m) | (m) | $144.80M | (m) | (m) | $2.81B | (m) | $-138.70M | (m) | (m) | (m) | -1.04× |
| 2023-12-31 | (m) | (m) | $167.40M | (m) | (m) | $3.11B | (m) | $-3.40M | (m) | (m) | (m) | -49.24× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $166.20M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $87.50M | (m) | (m) | $3.10B | (m) | $192.90M | (m) | (m) | (m) | 0.45× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $169.80M | (m) | (m) | $3.06B | (m) | $98.00M | (m) | (m) | (m) | 1.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |